Previous Close | 24.02 |
Open | 24.40 |
Bid | 23.97 x 900 |
Ask | 25.12 x 900 |
Day's Range | 23.75 - 24.70 |
52 Week Range | 14.21 - 37.75 |
Volume | |
Avg. Volume | 404,536 |
Market Cap | 635.747M |
Beta (5Y Monthly) | 2.58 |
PE Ratio (TTM) | 6.33 |
EPS (TTM) | 3.76 |
Earnings Date | Nov 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 56.31 |
Subscribe to Yahoo Finance Plus to view Fair Value for ARCT
In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare industry is one of the biggest industries in the world. […]
SAN DIEGO, December 04, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.m.
Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.